Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Meng Su Zeng

Status: Unknown

Conditions: Adenocarcinoma of Head of Pancreas

Study type: Observational

Funder types: Other

Identifiers

NCT01455610

ZMS-001

Details and patient eligibility

About

The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.

Enrollment: 140 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with (or suspected) pancreatic head cancer
• Being examined by contrasted-enhanced MDCT
• Receiving surgical treatment (including palliative surgery) in all research centers

Exclusion criteria

• Patients having (or suspected) pregnancy or breast-feeding
• Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs)
• Patients receiving ERCP before contrasted-enhanced MDCT examination
• Patients without surgery because of a high degree of surgical risk